 Acute dietary NO 3 -intake increased VO 2 peak in patients with HF by 8±2% (P<0.05).
the effects of acute NO 3 -ingestion on exercise responses in eight patients with HFrEF using a randomized, double-blind, placebo-controlled, crossover design. Methods and Results: Plasma NO 3 -, nitrite (NO 2 -), and breath NO were measured at multiple time points and respiratory gas exchange was determined during exercise after ingestion of beetroot juice containing or devoid of 11. 
Introduction
Tens of millions of men and women around the world suffer from heart failure (HF), a disabling and often deadly affliction (2) . In approximately half of all such individuals, the ejection fraction (EF) of the heart is reduced (2) . However, regardless of the precise nature or etiology of the disease, i.e., HF with reduced EF (HFrEF) or HF with preserved EF (HFpEF), patients with HF exhibit dyspnea and diminished peak oxygen (O 2 ) uptake (VO 2 peak) during exercise (18, 19) . Along with declines in maximal muscle speed and power (12) , these abnormalities in aerobic exercise responses play a major role in the disability, loss of independence, and reduced quality of life that accompany HF. Perhaps more importantly, elevations in ventilatory demand and decreases in VO 2 peak (and in skeletal muscle contractile function (22) ) are highly predictive of mortality in patients with HF (3, 13, 26, 40) .
One factor contributing to the exercise intolerance of HF -especially HFrEF -may be a reduction in nitric oxide (NO) signaling. Along with its well-recognized role as a vasodilator, NO modulates numerous other physiological functions relevant to exercise performance, e.g., muscle contractility (10, 11, 12, 41) . There is considerable evidence, however, that NO bioavailability is diminished in HFrEF, as a result of both reduced NO production via the NO synthase (NOS) pathway (45) and more rapid destruction of NO due to increased oxidative stress (33) . For example, endothelial dysfunction is common in HFrEF (48), indicative of blunted NO activity. Breath NO levels, a biomarker of whole-body NO production, are also lower in patients with HFrEF (1, 8, 9) , as are the circulating concentrations of nitrite (NO 2 -) (31, 46) , the immediate degradation product of NO. The conversion of N-labeled nitrate (NO 3 -) has also been shown to be diminished in patients with HFrEF (24), demonstrating directly that NOS-mediated NO production is impaired. Finally, increasing NO bioavaiability via L-arginine supplementation has been shown to improve 6 min walk distance in patients with HFrEF (39) . Collectively, these data suggest that reduced NO signaling in HFrEF may contribute to the altered exercise responses described above.
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Although most of the NO in the body is produced via the NOS pathway, it is now recognized that production of NO from dietary NO 3 -is an important source as well (28) . In this enterosalivary pathway, ingested NO 3 -is reduced to NO 2 -with aid of the mouth microbiota and then to NO in the tissues via a number of endogenous catalysts (43) . This last step is enhanced at low pO 2 The purpose of the present proof-of-concept study was to test the hypothesis that acute dietary NO 3 -intake would reduce ventilatory demands, increase VO 2 peak, and improve exercise performance in patients with HFrEF. We chose to study patients with HFrEF instead of HFpEF because evidence of reduced NO bioavailability is strongest in this population (vida supra). We focused specifically on ventilatory responses and VO 2 peak because of their importance as determinants of exercise capacity and predictors of survival in patients with HFrEF (3, 13, 26, 40) . Furthermore, since improvements in economy or efficiency are believed to be an important mechanism by which dietary NO 3 -enhances performance in other subject groups (5,36), we designed our study to carefully quantify not only gross but also delta efficiency during exercise, as the latter is a more direct indicator of muscle contractile efficiency (41) .
Materials and Methods

Subjects:
The subjects in this study were patients ≥18 y of age with HFrEF (i.e., EF <45%) who were on stable medical therapy (i.e., no addition, removal, or change in medication dose of >100% in the last 3 mo). Each underwent a physical exam, medical history, and blood tests for fasting chemistries. In (30) . Finally, subjects treated with organic nitrates (e.g., trinitroglycerin) were also excluded. After screening of 33 subjects, 10 subjects were enrolled in the study, with eight completing the entire protocol as planned (Fig. 1) . One subject was unable to achieve a steady-state at even 20 W, such that their gross and delta efficiency and VT could not be determined. Data from another subject were excluded when subsequent analysis of their plasma samples demonstrated that they inadvertently received NO 3 -during both trials. Approval for the study was obtained from the Human Subjects Office at Indiana University and the Human Research Protection Office at Washington University School of Medicine, and all subjects provided written, informed consent.
Experimental design and protocol: Upon enrollment, each patient was studied using a randomized, double-blind, placebo-controlled, crossover design ( Fig. 2, top panel) . During one trial, they were tested 2 h after ingesting 140 mL of a concentrated BRJ supplement (Beet It Sport®, James White Drinks, Ipswich, UK) containing 11.2 mmol of NO 3 -. During another trial, they were tested after ingesting the same volume of NO 3 --depleted BRJ. This placebo is prepared by the manufacturer by extracting NO 3 -from BRJ using an ion exchange resin and is indistinguishable from the standard product in packaging, color, texture, taste, and smell, and does not alter plasma NO 3 - or NO 2 -concentrations or breath NO levels. There was a minimum 1 wk washout period between trials. To limit variation in baseline NO 3 -, NO 2 -, and NO levels, subjects were instructed to avoid high NO 3 -foods for 10 d prior to intervention and throughout the study. Subjects were also instructed to avoid food, caffeine, alcohol, and exercise for 12
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Subjects arrived at the Clinical Research Unit of Washington University School of Medicine in the morning after fasting overnight. Baseline heart rate and blood pressure were first measured, after which an antecubital venous catheter was inserted and a blood sample was obtained. Plasma was rapidly separated via centrifugation and frozen at -80° C for subsequent determination of NO 3 -and NO 2 -concentrations using a dedicated HPLC system (ENO-30, Eicom USA, San Diego, CA). Briefly, plasma was thawed on ice, mixed 1:1 with methanol, and centrifuged at 4° C for 10 min at 10,000 g. A 10 μL aliquot of the protein-poor supernatant was then injected into the HPLC, wherein NO 3 -and NO 2 -were isolated via a separation column, NO 3 -reduced to NO 2 -on a cadmium column, and both reacted with Griess reagent then detected spectrophotometrically at 540 nm. Plasma NO 3 -and NO 2 -concentrations were calculated based on integrated peak areas compared to those of authentic standards. This method was highly reproducible, with test-retest correlation coefficients of 0.99 and 0.98 for NO 3 -and NO 2 -, respectively. To further reduce variability, all samples from a single subject were analyzed together.
Breath NO level, a biomarker of whole-body NO production (1, 8, 9, 35) , was also measured once at this time using a portable electrochemical analyzer (NIOX VERO, Circassia Pharmaceuticals Inc., Chicago, IL)
following American Thoracic Society guidelines. These measurements were repeated 1 and 2 h after the subject had ingested the BRJ, and also 10 min after completion of all exercise testing (i.e., at ~3 h). The latter consisted of submaximal steady-state and maximal incremental exercise on a semi-recumbent cycle ergometer (Lode, Gronigen, The Netherlands) (Fig. 2, bottom panel) . Semi-recumbent cycle ergometry was chosen to minimize use of upper body musculature, thus aiding interpretation of any observed changes in exercise efficiency. After adjustment of the seat position, subjects first pedaled the ergometer at 60 rpm for 6 min each at 20, 40, and 60 W while respiratory gas exchange was measured continuously using a ParvoMedics 2900 metabolic cart (ParvoMedics, Sandy, UT). Heart rate, blood pressure, and perceived exertion (7) were determined during the last 30 s of each stage. Following 10 min of rest, subjects resumed pedaling at 60 W for 1 min, after which the power output was incremented by 10 W/min (47) until volitional fatigue. Respiratory gas exchange and heart rate were monitored continuously and blood pressure was measured periodically throughout the test and also immediately following cessation of exercise.
Data analyses: Respiratory gas exchange data collected during the final 2 min of each stage of the submaximal exercise test were averaged and used in all subsequent analyses. Gross efficiency was calculated as the ratio of external power to metabolic power (37), multiplied by 100%. Delta efficiency,
i.e., the slope of the relationship between external and metabolic power, and the metabolic cost of unloaded cycling, i.e., the y intercept of this relationship, were determined by regression analysis (40) .
Similarly, during the maximal exercise test the oxygen uptake efficiency slope (OUES; Ref. was determined using the V-slope method (6). Peak power was defined as the average power during the last 1 min of exercise. VO 2 peak was defined as the highest VO 2 measured over any 1 min period.
Statistical analyses were performed using GraphPad Prism version 7.02 (GraphPad Software, La Jolla, CA). Normality of data distribution was first tested using the D'Agostino-Pearson omnibus test.
Data were subsequently analyzed using two-way (treatment x order) ANOVA, with subject as a repeated measures factor within treatment. A P value of <0.05 was considered significant. Primary outcome variables were changes in ventilatory responses and VO 2 peak in response to dietary NO 3 -. Secondary outcome variables were changes in exercise performance and efficiency; all other variables measured were considered tertiary.
Results
Patient characteristics. Characteristics of the patients are shown in (Fig. 3, top and middle panels) or in breath NO levels (Fig. 3, bottom panel) occurred during the placebo trial. In contrast, ingestion of NO 3 --containing BRJ elevated (P < 0.01) plasma NO 3 -concentrations approximately 10-fold after 1 h, with this increase being maintained for the remainder of the experiment (Fig. 3, top   panel) . Concentrations of the downstream metabolites of NO 3 -, i.e., plasma NO 2 -and breath NO, were also significantly elevated by NO 3 -intake, albeit to a much lesser degree (Fig. 3 , middle and bottom panels). The increase in plasma NO 2 -also seemed to lag behind that of NO 3 -, achieving statistical significance only after 2 h and peaking at 10 min post-exercise. These findings are consistent with the important rate-limiting role played by oral bacteria in the enterosalivary pathway of NO production (28).
Responses to submaximal exercise. Despite the increase in NO bioavailability resulting from NO 3 -ingestion, no differences were observed in VO 2 , ventilation, ventilatory equivalents (i.e., Ve/VO 2 and Ve/VCO 2 ), respiratory exchange ratio, or gross efficiency during submaximal steady-state exercise ( Table 2) . Delta efficiency was also unaffected by dietary NO 3 -intake, averaging 26.2 ± 2.5 and 24.9 ± 1.8% in the placebo and nitrate trials, respectively (P = NS). The metabolic cost of unloaded cycling was also unchanged, averaging 200 ± 27 W, or 1.87 ± 0.07 W/kg, in the placebo trial and 215 ± 27 W, or 2.06 ± 0.14 W/kg, in the nitrate trial (P = NS). Finally, no significant differences were observed in heart rate, systolic or diastolic blood pressures, or in perceived exertion ( Table 2) .
Responses to maximal exercise. Ingestion of NO 3 -did not alter ventilatory responses during the incremental exercise test, regardless of whether the data were analyzed to determine the OUES, Ve/VCO 2 slope, or VT ( Table 3) . Respiratory exchange ratio, heart rate, and systolic and diastolic blood
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Discussion
The purpose of the present study was to determine the effects of dietary NO 3 -supplementation on the responses to aerobic exercise in patients with HFrEF. Using a double-blind, placebo-controlled, crossover design, we found that acute ingestion of 11.2 mmol of NO 3 -resulted in significant increases in exercise duration, peak power, and VO 2 peak during an incremental cycle ergometer exercise test. Contrary to our initial hypothesis, however, this was not accompanied by any changes in the ventilatory response (i.e., ventilatory equivalents, OUES, Ve/VCO 2 slope, or VT) during submaximal or maximal exercise. There were also no changes in either gross or delta efficiency during steady-state exercise.
As stated above, we found that acute ingestion of NO 3 -enabled patients with non-ischemic HFrEF to exercise longer and to achieve a higher peak power output during incremental exercise. This improvement in performance was accompanied by an increase in VO 2 peak. , or +8 ± 2%, may prove to be clinically significant. In particular, in a previous cross-sectional study of patients with HFrEF one of us (LRP) found that for every 1 mL . min -1. kg -1 increase in VO 2 peak there was a 5% decrease in the annual risk of death or transplantation (38) . A quantitativelysimilar relationship was observed between changes in VO 2 peak and disease outcome in the longitudinal HF-ACTION trial (44). At least theoretically, then, the acute dietary NO 3 --induced increase in VO 2 peak observed in the present study would translate into almost a 10% reduction in annual risk. Additional research will be needed to test this hypothesis, especially in those at greatest risk (such as the three patients mentioned above).
It is also worth noting that the magnitude of the improvement in VO 2 peak that we observed is comparable to that typically resulting from standard-of-care drug therapies or from endurance exercise training in patients with HF, both of which provide salutatory effects. Specifically, a number of previous studies have demonstrated that chronic treatment of HFrEF patients with a beta blocker or ACEi/ARB increases VO 2 peak by approximately 10% (e.g., 14, 16, 32) . Improvements in VO 2 peak with exercise training are also similar (22) . Intriguingly, the 8% enhancement of VO 2 peak that we found in response to acute dietary NO 3 -intake occurred in patients with HFrEF already on optimal medical therapy, including use of a beta blocker and, in most cases, an ACEi/ARB, indicative of an additive effect. Future studies will
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Although the present results indicate that acute dietary NO 3 -intake increases VO 2 peak in patients with HFrEF, the specific mechanisms responsible for this beneficial response cannot be determined from the present data. From the perspective of the cardiovascular Fick equation, though, an increase in VO 2 peak could only result from an increase in heart rate, stroke volume (SV), and/or arteriovenous O 2 difference (a-vO 2 diff) at peak exercise. Indeed, at peak exercise heart rate tended to be higher and diastolic blood pressure tended to be lower, suggesting that the dietary NO 3 --induced increase in VO 2 peak we observed may have been the result of a greater cardiac output in a setting of reduced total peripheral resistance. Given the direct effects of NO on arteriolar smooth muscle, the latter response might be expected. In addition, recent data indicate that dietary NO 3 -intake also enhances vasodilation in contracting muscle by reducing sympathetic nerve activity (36) . Again, however, in the absence of direct measurements the mechanism(s) responsible for the increase in VO 2 peak observed in the present study remain unknown.
Although acute dietary NO 3 -intake resulted in a significant increase in performance and VO 2 peak, there were no changes in the ventilatory response to exercise, quantified as either Ve/VO 2 found in HF, minimize involvement of non-active tissues, and allow assessment of not only gross but also delta efficiency, we also found acute dietary NO 3 -intake did not alter the energy requirements of submaximal exercise. As suggested by Zamani et al. (50) , this may reflect differences between patients with HF and young, healthy control subjects in age or in the factors controlling mitochondrial respiration during exercise. Regardless, the present data demonstrate that, at least in patients with HFrEF, acute dietary NO 3 -intake can increase performance and VO 2 peak even in the absence of any changes in energy demand at a given power output.
There are a number of limitations to the present study. First, we studied a relatively small number of individuals, and therefore may have failed to detect some true effects of NO 3 -supplementation, e.g., a decrease in blood pressure. However, our sample size was comparable to those of similar previous studies of dietary NO 3 -intake on exercise responses in patients with HFrEF (20, 25) , and was adequate to detect changes in one of our primary outcomes, i.e., VO 2 peak. Second, as previously discussed we did not directly measure central or peripheral determinants of VO 2 peak, and therefore cannot determine the mechanisms responsible for the improvement that was observed. This does not, however, negate our primary finding that dietary NO 3 -supplementation increases exercise capacity and VO 2 peak in patients with HFrEF. Finally, we studied only the effects of acute ingestion of 
